News and Announcements

GSK's blood cancer treatment approved in Japan

By Benjamin Chiou

Date: Monday 19 May 2025

(Sharecast News) - GSK's Blenrep treatment has been approved by Japanese regulators when in combination for relapsed or refractory multiple myeloma, marking the second major approval of its kind for the drug, with more expected in 2025.
The pharma giant said on Monday that the Ministry of Health, Labour and Welfare...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page